424 results on '"Eclache, Virginie"'
Search Results
2. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
3. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53
4. Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia
5. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
6. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
7. The Mutator Pathway Is a Feature of Immunodeficiency-Related Lymphomas
8. Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
9. The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots
10. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
11. “Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain
12. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
13. The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significance.
14. Intérêt de la cytogénétique et de la biologie moléculaire pour le diagnostic des syndromes lymphoprolifératifs B
15. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
16. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
17. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
18. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
19. Characterisation of a New Clinical Presentation of Chronic Lymphocytic Leukemia with Symptomatic Nasopharyngeal Mucosa Involvement
20. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience
21. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases
22. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
23. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
24. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogénétique Hématologique study
25. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )
26. KMT2A-ARHGEF12, a Therapy Related Fusion with Dismal Prognosis.
27. Old DAT and new data: Positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients
28. Detection of chromosomal abnormalities associated with chronic lymphocytic leukemia: what is the best method?
29. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course
30. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy
31. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
32. Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement
33. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving and MYC and TP53
34. Abstract 608: The MPS1 inhibitor S81694 is active in acute myeloid leukemia (AML)
35. Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort
36. Réponse aux inhibiteurs de tyrosines kinases des patients avec néoplasies myéloïdes et transcrits rares
37. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia
38. Évolution de l’hématopoïèse clonale à long terme dans le contexte d’allogreffe
39. The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants
40. A primitive plasma cell leukemia with immunoglobulin (Ig) E
41. Clinical and biological features associated with taste loss in internal medicine patients. A cross-sectional study of 100 cases
42. The role of lenalidomide in the management of myelodysplasia with del 5q
43. Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients
44. The CADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
45. Occurrence of myelodysplastic syndrome in 2 patients with reticular dysgenesis
46. M0 AML, clinical and biologic features of the disease, includingAML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)
47. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
48. Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group
49. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)
50. t(5;11)(q33;q13) NUMA1/PDGFRB a novel fusion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.